PET/CT scan test for small cell lung cancer marker DLL3
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (or in a pediatric arm, at least age 4) and can give informed consent
- You have a confirmed small cell lung cancer, or another eligible neuroendocrine tumor (or specific other tumor types as listed)
- Recent imaging shows at least one tumor spot (on CT/MRI, or on PET scans, or new bone metastases on scan) within the last 12 weeks when required
- You can have the scan without extra sedation/anesthesia, and you can safely complete PET/CT even with the weight limit
- You’re able to provide tumor tissue for a DLL3 test (or for some prostate cases, you may need to agree to a guided biopsy if tissue isn’t available)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan (68Ga-PFD3) to take pictures of small cell lung cancer tumors. The goal is to see if this scan can help doctors better diagnose and evaluate the cancer, which may guide treatment decisions.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
This early-phase trial tests a new radioactive drug that targets a protein (DLL3) found on some lung and prostate cancer cells. It aims to see if this drug is safe and effective for patients whose cancer has progressed after standard treatment.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.